Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.5mL Intramuscular Injection Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 3, 2026, 7:26 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

NCT05329961
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Gardasil9
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
4 Years to 8 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

NCT00829595
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

NCT00511095
View directory record Official record
Conditions
Hepatitis B
Interventions
HEPLISAV
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
11 Years to 55 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Boardman, Ohio • Grove City, Pennsylvania • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 3, 2026, 7:26 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

MVA-BN-RSV Vaccine Trial

NCT05238025
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
60 Years and older
Enrollment
20,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
105
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01147068
View directory record Official record
Conditions
Influenza
Interventions
0.5mL Intramuscular Injection
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Overland Park, Kansas • Omaha, Nebraska • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2012 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

NCT02718469
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
Ebola Vaccine - low dose, Ebola Vaccine - mid dose, Ebola Vaccine - high dose, Placebo
Biological
Lead sponsor
Auro Vaccines LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 3, 2026, 7:26 AM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
View directory record Official record
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 3, 2026, 7:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effect of Obesity on Immune Response to Pneumovax 23

NCT02471014
View directory record Official record
Conditions
Obesity
Interventions
Pneumovax 23, Blood tests, Questionnaires
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 4 Interventional Results available

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

NCT01034358
View directory record Official record
Conditions
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Interventions
Human Papillomavirus Vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 3, 2026, 7:26 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
Biological
Lead sponsor
Vaxxinity, Inc.
Industry
Eligibility
16 Years and older
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01612000
View directory record Official record
Conditions
Influenza
Interventions
PanBlok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Omaha, Nebraska • Rochester, New York • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

NCT01709019
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 3, 2026, 7:26 AM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

NCT02079701
View directory record Official record
Conditions
Pneumonia, Acute Respiratory Disease
Interventions
23-valent pneumococcal vaccine, Placebo
Biological
Lead sponsor
Naval Health Research Center
Federal
Eligibility
Not listed
Enrollment
152,723 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
5
States / cities
San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

NCT02464163
View directory record Official record
Conditions
Influenza
Interventions
Panblok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Mobile, Alabama • DeLand, Florida • Savannah, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent HPV vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Dose Ranging Study With Adjuvant Patch

NCT00532792
View directory record Official record
Conditions
Pandemic Influenza
Interventions
A/H5N1, Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Vallejo, California • Miami, Florida • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 3, 2026, 7:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 3, 2026, 7:26 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment

NCT06391125
View directory record Official record
Conditions
Syphilis Infection, Benzathine Penicillin Adverse Reaction
Interventions
normal Saline, Lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 3, 2026, 7:26 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 3, 2026, 7:26 AM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 3, 2026, 7:26 AM EDT